PRKDC and acute myeloid leukemia: In sum, our results suggest that incorporating small-molecule inhibitors of DNA-PK and MEK1/2-ERK1/2 pathways may alleviate intrinsic and extrinsic resistance to chemotherapy agents, respectively, thereby enhancing the efficacy of chemotherapy regimens and improving clinical outcomes for pediatric AML patients.